Shares of PetMed Express, Inc. (NASDAQ:PETS) have been given a consensus rating of “Buy” by the seven brokerages that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $44.75.

A number of equities analysts have recently commented on PETS shares. Craig Hallum downgraded shares of PetMed Express from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Northcoast Research raised shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $54.00 price objective for the company in a report on Monday, July 24th. Noble Financial reaffirmed a “hold” rating on shares of PetMed Express in a report on Wednesday, July 26th. BidaskClub downgraded shares of PetMed Express from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 22nd. Finally, Sidoti raised shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Thursday, August 24th.

Shares of PetMed Express (NASDAQ PETS) opened at 35.56 on Monday. The company has a market cap of $721.58 million, a P/E ratio of 27.35 and a beta of 1.03. PetMed Express has a 12 month low of $18.90 and a 12 month high of $50.90. The company’s 50 day moving average is $41.68 and its 200-day moving average is $33.21.

PetMed Express (NASDAQ:PETS) last released its quarterly earnings data on Monday, July 24th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.07. The company had revenue of $79.66 million during the quarter, compared to the consensus estimate of $77.32 million. PetMed Express had a net margin of 10.34% and a return on equity of 28.67%. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the firm earned $0.32 EPS. Analysts expect that PetMed Express will post $1.45 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/17/petmed-express-inc-pets-given-consensus-rating-of-buy-by-analysts.html.

In related news, Director Ronald J. Korn sold 5,000 shares of PetMed Express stock in a transaction dated Friday, July 28th. The shares were sold at an average price of $48.18, for a total transaction of $240,900.00. Following the completion of the transaction, the director now directly owns 67,333 shares of the company’s stock, valued at approximately $3,244,103.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert C. Schweitzer sold 2,500 shares of PetMed Express stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $49.18, for a total transaction of $122,950.00. Following the transaction, the director now directly owns 88,834 shares of the company’s stock, valued at $4,368,856.12. The disclosure for this sale can be found here. Insiders have sold a total of 19,333 shares of company stock valued at $949,730 over the last ninety days. 4.00% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in PetMed Express by 4.3% during the 1st quarter. Vanguard Group Inc. now owns 1,075,251 shares of the company’s stock valued at $21,656,000 after purchasing an additional 44,560 shares during the last quarter. WBI Investments Inc. bought a new position in PetMed Express during the 2nd quarter valued at about $3,943,000. Engineers Gate Manager LP bought a new position in PetMed Express during the 2nd quarter valued at about $1,939,000. Oaktop Capital Management II L.P. bought a new position in PetMed Express during the 2nd quarter valued at about $15,171,000. Finally, Wells Fargo & Company MN lifted its holdings in PetMed Express by 3.3% during the 1st quarter. Wells Fargo & Company MN now owns 348,244 shares of the company’s stock valued at $7,014,000 after purchasing an additional 10,971 shares during the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

About PetMed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.